Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranibizumab.

Stephanie K A Blick1, Gillian M Keating, Antona J Wagstaff

  • 1Wolters Kluwer Health/Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Ranibizumab injections effectively maintained or improved vision in patients with wet age-related macular degeneration (AMD). This treatment demonstrated superiority over other therapies, offering a new option for managing this common cause of vision loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Medical Research
  • Pharmacology

Background:

  • Choroidal neovascularisation is a key factor in wet age-related macular degeneration (AMD).
  • Vascular Endothelial Growth Factor A (VEGF-A) plays a critical role in the development of neovascular AMD.
  • Effective treatments are needed to preserve or restore visual acuity in AMD patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of ranibizumab in treating neovascular (wet) age-related macular degeneration (AMD).
  • To compare ranibizumab treatment with existing therapies like verteporfin photodynamic therapy and sham procedures.
  • To assess the potential benefits of combination therapy with ranibizumab and verteporfin.

Main Methods:

  • Phase III clinical trials involving patients with neovascular AMD.

Related Experiment Videos

  • Monthly intravitreal injections of ranibizumab (0.3 or 0.5 mg) for up to 2 years.
  • Comparison groups included sham injection, verteporfin photodynamic therapy, and sham photodynamic therapy.

    • Main Results:

    • Ranibizumab injections maintained or improved visual acuity more effectively than control treatments.
    • Combination therapy of ranibizumab and verteporfin showed superiority over verteporfin alone in specific patient subgroups.
    • Serious ocular adverse events were uncommon and primarily related to the injection procedure or the drug itself.

    Conclusions:

    • Monthly intravitreal ranibizumab is an effective treatment for neovascular AMD, offering significant visual acuity benefits.
    • Ranibizumab represents a valuable therapeutic option for patients suffering from wet AMD.
    • The safety profile of ranibizumab is acceptable, with most adverse events being procedural or drug-related and uncommon.